Immunotherapy for Stage III NSCLC: Durvalumab and Beyond

Fitzpatrick, Orla; Naidoo, Jarushka

doi:10.2147/lctt.s305466

Cited by 6 publications

(11 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…USA, Australia, Canada, Japan, Singapore, and India have approved durvalumab consolidation treatment added in chemoradiation therapy for patients with unresectable stage III NSCLC, while in the EU, only the patients with tumors expressing PD-L1≥1% can use durvalumab [33,34].…”

Section: Durvalumabmentioning

confidence: 99%

“…Moreover, durvalumab consolidation treatment is proved cost-effective compared to chemotherapy alone [34].…”

Section: The Advantagesmentioning

confidence: 99%

“…Pneumonitis occurs both in monotherapy and in combination treatment, presenting as immunerelated pneumonitis bilaterally with a larger area and radiation pneumonitis unilaterally with smaller areas respectively. Corticosteroid therapy can be a kind of management for immune-mediated pneumonitis, which can't be used before the treatment but after the process [34].…”

Section: Shortcomings and Unsolved Issuesmentioning

confidence: 99%

“…Based on the MoA, durvalumab has a potential to impact pregnancy, which is proven in a mouse model finally resulting in fetal loss but hasn't been examined whether it is true for humans. It is not expected to have metabolic drug-drug interactions with durvalumab but currently, no studies have been conducted in terms of the formal pharmacokinetic interaction [34].…”

Section: Shortcomings and Unsolved Issuesmentioning

confidence: 99%

See 3 more Smart Citations

Immune Checkpoint Inhibitors in Lung Cancer

Chen¹,

Jian²,

Yuan-dong³

2022

HSET

View full text Add to dashboard Cite

With the fast increase in morbidity and mortality, lung cancer has become one of the greatest threats to physical health in some countries. Immune checkpoint inhibitors (ICIs) have a significant influence on the treatment landscape of lung cancer, including non-small cell lung cancer (NSCLC). This review highlights the most important ICIs used in lung cancer at present, anti-CTLA-4 and PD-1/L1. The application status, efficacy, shortcomings and prospect of each drug, including Ipilimumab (CTLA-4), Nivolumab, Pembrolizumab, and Durvalumab (PD-1/L1), are listed to show the drug indication in the current market. By comparing different drugs, the direction of ICI drug development can be more precise, which can have an important influence on choosing drugs for lung cancer treatment.

show abstract

Section: Durvalumabmentioning

confidence: 99%

“…Moreover, durvalumab consolidation treatment is proved cost-effective compared to chemotherapy alone [34].…”

Section: The Advantagesmentioning

confidence: 99%

Section: Shortcomings and Unsolved Issuesmentioning

confidence: 99%

Section: Shortcomings and Unsolved Issuesmentioning

confidence: 99%

See 2 more Smart Citations

Immune Checkpoint Inhibitors in Lung Cancer

Chen¹,

Jian²,

Yuan-dong³

2022

HSET

View full text Add to dashboard Cite

show abstract

“…It has been demonstrated in real-world settings that patients with higher PD-L1 expression may benefit more from durvalumab treatment. Unfortunately, autoimmune disease history and some comorbidities may prevent its use and reduce its effectiveness [110].…”

mentioning

confidence: 99%

A Comparative and Comprehensive Review of Antibody Applications in the Treatment of Lung Disease

Song

2022

Life

View full text Add to dashboard Cite

Antibodies are a type of protein produced by active B cells in response to antigen stimulation. A series of monoclonal antibodies and neutralizing antibodies have been invented and put into clinical use because of their high therapeutic effect and bright developing insight. Patients with cancer, infectious diseases, and autoimmune diseases can all benefit from antibody therapy. However, the targeting aspects and potential mechanisms for treating these diseases differ. In the treatment of patients with infectious diseases such as COVID-19, neutralizing antibodies have been proposed as reliable vaccines against COVID-19, which target the ACE2 protein by preventing virus entry into somatic cells. Monoclonal antibodies can target immune checkpoints (e.g., PD-L1 and CTLA-4), tyrosine kinase and subsequent signaling pathways (e.g., VEGF), and cytokines in cancer patients (e.g. IL-6 and IL-1β). It is debatable whether there is any connection between the use of antibodies in these diseases. It would be fantastic to discover the related points and explain the burden for the limitation of cross-use of these techniques. In this review, we provided a comprehensive overview of the use of antibodies in the treatment of infectious disease and cancer patients. There are also discussions of their mechanisms and history. In addition, we discussed our future outlook on the use of antibodies.

show abstract

Circular RNA circ_0000376 promotes paclitaxel resistance and tumorigenesis of non‐small cell lung cancer via positively modulating KPNA4 by sponging miR‐1298‐5p

Zhang

Sun

et al. 2023

Thoracic Cancer

View full text Add to dashboard Cite

Background Circ_0000376 could promote non‐small cell lung cancer (NSCLC) progression; however, the role of circ_0000376 in paclitaxel (PTX) resistance of NSCLC is still unknown. Methods Quantitative real‐time polymerase chain reaction (qRT‐PCR) and western blot were applied for measuring circ_0000376, microRNA‐1298‐5p (miR‐1298‐5p), and karyopherin subunit alpha 4 (KPNA4) expression. The half inhibitory concentration (IC50) of PTX was assessed by cell counting kit‐8 assay. 5‐ethynyl‐2′‐deoxyuridine assay, wound healing assay, transwell assay, and flow cytometry were performed to measure the proliferation, migration, invasion, and apoptosis of cells. The regulatory mechanisms of circ_0000376, miR‐1298‐5p, and KPNA4 were validated by dual‐luciferase reporter assay, RNA immunoprecipitation assay, and rescue experiments. Xenograft assay was used for the functional analysis of circ_0000376 in vivo. Results Circ_0000376 and KPNA4 expressions were upregulated, while miR‐1298‐5p expression was downregulated in PTX‐resistant tissues and cells. Circ_0000376 depletion promoted PTX sensitivity and apoptosis, while suppressing the proliferation, migration, and invasion of PTX‐resistant NSCLC cells. Furthermore, circ_0000376 could modulate KPNA4 expression by sponging miR‐1298‐5p. Rescue experiments showed that miR‐1298‐5p inhibition reversed the circ_0000376 depletion‐mediated anticancer effects and PTX sensitivity. Moreover, miR‐1298‐5p inhibited PTX resistance and tumorigenesis of PTX‐resistant cells, which were abolished by KPNA4 overexpression. In addition, circ_0000376 knockdown suppressed tumor growth and enhanced PTX sensitivity in vivo. Conclusion Circ_0000376 facilitated PTX resistance and tumorigenesis of NSCLC by miR‐1298‐5p/KPNA4 axis, suggesting an underlying therapeutic strategy for NSCLC.

show abstract

Immunotherapy for Stage III NSCLC: Durvalumab and Beyond

Cited by 6 publications

References 83 publications

Immune Checkpoint Inhibitors in Lung Cancer

Immune Checkpoint Inhibitors in Lung Cancer

A Comparative and Comprehensive Review of Antibody Applications in the Treatment of Lung Disease

Circular RNA circ_0000376 promotes paclitaxel resistance and tumorigenesis of non‐small cell lung cancer via positively modulating KPNA4 by sponging miR‐1298‐5p

Contact Info

Product

Resources

About